Recently (1), we described a new genetic system that is HLA-DQ-related . Two alleles, 2B3 and TA10, can be recognized serologically . The 2133 specificity detected with the 11133 mAb was previously described (2) as a DQwl-related specificity. The TA 10 specificity is DQw3-related and was first. described by Maeda (3) with the TA 10 mAb. TA10 can also be detected with alloantisera (4) . Recently, an absolute correlation of the TA10 specificity with a RFLP using a DQ(O probe has been described (5).
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2113 and TAIO . Two specific fragments could be shown in his RFLP ; one was inherited by three children that were DR4+, TA 10 +, and the other segregated to the other two children that were DR4+, 2B3+. The latter two children happened to be diabetic patients .
This observation, together with other reports, suggested that other markers (i .e ., DQ#) in addition to DR4 may influence disease susceptibility, notably to type I diabetes (5, 8) . Here we present data concerning the DQ-related TA10/2B3 polymorphism and type I diabetes mellitus, as well as rheumatoid arthritis.
Materials and Methods Cells. 14 EBV-transformed cell lines from DR4 homozygous typing cells with HLADw4, Dw 10, Dw 13, Dw 14, and Dw 15 specificities were used as described previously (7) .
64 children with type I diabetes mellitus attending the outpatient clinic for diabetes at the Sophia Children's Hospital in Rotterdam were studied. Blood from 116 patients with rheumatoid arthritis was made available by Dr . Westedt and Dr . Cats from the Department of Rheumatology of the University Hospital, Leiden .
A group of 297 healthy individuals served as control population for the 2133 and TA 10 specificities. In this group, 14 DR3+ DR4+ individuals were observed . In more recently DR typed controls, another 24 DR3+ DR4+ individuals were also typed for 2113 and TA 10 . All patients and controls were of Dutch caucasoid origin .
Serological Typings. HLA-DR and DQ typings were performed by two-color fluorescence (TCF) (9) or propidium iodide (PI) technique (10) with a set of highly selected class II antisera . The 2133 and TA10 specificities were determined with the mAbs 11113 and TA10, respectively (2, 3) .
Biochemical Techniques. Southern blot analyses with the DQ# cDNA probe were performed as described previously (7) . Two-dimensional gel electrophoresis was conducted as described by Goyert et al . (11) . HLA-DQ molecules were isolated with the DQ-specific mAb SPV-L3 (12) .
Statistical Analysis. Associations between the TAIO and 2113 specificities and type I diabetes or rheumatoid arthritis were calculated with the Woolf-Haldane method (13) .
Results and Discussion
Serological and Biochemical Studies. The 2B3/TA10 polymorphism was investigated in a group of DR4+ HTCs including Dw4, Dw 10, Dw 13, Dw 14, and Dw 15 specificities. TA 10 was detected on some Dw4 and some Dw 13 HTCs, which is in agreement with earlier observations (14) . 2133 was present on the majority of HTCs . Two HTCs appeared to carry both the TA 10 and 2133 alleles, indicating heterozygosity for this DQ-related system . 11 of these DR4 HTCs were analyzed at the product level. HLA-DQ molecules were isolated with a monomorphic anti-DQ mAb SPV-L3 (12) . HLA-DQ molecules appeared to focus in three different positions due to S chain pI differences (6) .
The genomic DNAs isolated from the 14 DR4 HTCs were also studied for RFLP as obtained after digestion with various restriction enzymes and hybridization with a DW probe (7) . When the enzyme Eco RI was used, we saw two polymorphic fragments of 15 and 20 kb within the RFLP obtained with the DR4 cells. Table I shows that all 2113 + HTCs contained the DQ02 or DQ03 chain (as shown by IEF), as well as the 20-kb fragment in RFLP, whereas the presence of TA10 is closely associated with the presence of DQ#I chains and the presence of a 15-kb fragment . The only exception was an HTC that only had the DQ#2 chain and the 20-kb fragment in RFLP, but was clearly heterozygous for the serologically defined 2113 and TA10 specificities on four different typing occasions (6, 7) .
Both variants of this 2B3/TAIO-related polymorphism were observed within the groups of Dw4 and Dw13 HTCs . Furthermore, one Dw4 HTC was heterozygous for 2B3/TA I0, as detected by serology, by two-dimensional gel electrophoresis, and by Southern blot analyses indicating that this polymorphism is independent of HLA-D.
2B3/TA10 and Disease Susceptibility . Previous studies (5, 8) , as well as our observations in a family with two diabetic patients, did suggest that DR4-2B3 and not DR4-TA 10 might be associated with susceptibility to type I diabetes . Therefore, we tested type I diabetes patients and controls for 2113 and TA 10 in addition to HLA-DR, and looked for an association with 2113 and/or TA10 . The data were analyzed taking into account the known DR phenotypes (DR2, 3, and 4) associated with type I diabetes (15) . Because only 1 patient out of 65 was DR2+, we did not include either this patient or DR2+ controls in the analysis. As shown in Table 11 , there was a very significant (relative risk <0.10) negative association of TA 10 with this disease. This was not only the case in DR4+, but also in DR4-individuals. The only exception was the group of individuals with the DR4/x phenotype, suggesting that at least in DR4+ individuals, 2113 might be associated with susceptibility, rather than TA10 with resistance to type I diabetes . Table III shows that this was not the case. We did not observe a significant association of 2113 with diabetes in either DR4-or DR4+ individuals, with the exception of DR3/4 individuals. The latter, however, is also explained by the negative association with TA10, as shown in Table 11 . Therefore, the simplest interpretation of the data shown in Table II and III is that TA10 is associated with resistance to type I diabetes, at least in DR2-individuals. The absence of a significant association of TA 10 in DR4/x individuals suggests that on certain haplotypes (i .e ., DR non-2, non-3, non-4) TA10 may not provide resistance to type I diabetes in the presence of DR4 on the other haplotype. In other words, this might indicate a certain interaction between (products of) haplotypes, such as complementation . This hypothesis may be answered by family studies. That DR4 is indeed also associated with susceptibility in TA10+ individuals can be seen from the TA 10+ rows of Table II ; 4 out of 4 TA 10+ patients, as compared with 25 out of 63 (see note) TA10 + controls, were positive for DR4 (relative risk 13 .6; p, 0.0025) . In conclusion, in addition to the known association of HLA-DR2 with resistance to type I diabetes (15, 16) , the TA10 allele of HLA-DQ(3 appears to be a new marker for resistance to this disease. This indicates that not only HLA-DR but also other genes in the HLA-D region may influence the development of type I diabetes, as already suggested previously (5, (15) (16) (17) (18) . From a previous study (19) we concluded that such genes have to be situated telomeric from HLA-DP. Therefore, HLA-DQ might not only be a marker for but rather be the actual resistance gene.
In contrast to these significant effects of the 2B3/TA 10 DQ polymorphism on the development of type I diabetes, no association was observed in a group of 116 rheumatoid arthritis patients (data not shown) . This clearly indicates that different HLA-linked genes confer susceptibility or resistance to these two HLA-DR4-associated diseases, confirming previous observations (20 Summary A new HLA-DQ-related genetic system with two alleles, 2133 and TA10, defined serologically by mAbs and alloantisera, showed an almost perfect correlation with charge differences on DQ# molecules, as well as with two polymorphic DNA fragments hybridizing with a DQ# probe and various restriction enzymes on a panel of 14 DR4 + homozygous typing cells. It was therefore concluded that the serologically defined alleles 2113 and TA 10 are coded by the DQ# gene and situated on the HLA-DQ# chain. This 2133/TA10 polymorphism is independent of HLA-D and segregates with HLA in families . The TA 10 allele appears to be a new marker for resistance to type I diabetes, which is independent from the known resistance marker DR2, whereas no association was observed between this DQ# polymorphism and rheumatoid arthritis.
